SCHEDULE 13G/A: Opaleye Management Reduces Stake in Protara Therapeutics Below 5%

Opaleye Management, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.71% in Protara Therapeutics, Inc., indicating a reduction below the 5% threshold.

Summary

• Opaleye Management, Inc. reported beneficial ownership of 1,730,000 shares of Protara Therapeutics, Inc. common stock.
• This represents 4.71% of the total class of securities, indicating that Opaleye Management, Inc. no longer holds 5% or more of the company's common stock.
• Opaleye Management, Inc. holds shared voting power over all 1,730,000 shares.
• Opaleye Management, Inc. holds shared dispositive power over all 1,730,000 shares.
• The filing is an Amendment No. 2 to a previous Schedule 13G, reflecting a change in their reported beneficial ownership.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership and does not contain qualitative statements or performance metrics that would indicate a positive or negative sentiment. The reduction in stake below 5% is a factual change, not inherently positive or negative within the document itself.

Future Outlook

NA

Management Comments

• Opaleye Management, Inc. certifies that, to the best of their knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor were they acquired or held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing reflects a change in a significant institutional investor's stake in a publicly traded biotechnology or pharmaceutical company, a common occurrence in the dynamic investment landscape.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional investor's stake could be interpreted by the market as a change in investor confidence, potentially influencing share price.

Key Dates

Keywords

Protara Therapeutics, Opaleye Management, SEC filing, Schedule 13G, beneficial ownership, common stock, investment adviser